Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.51 |
| ▸ | TOP2A | P11388 | 1/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 12/20 | 0.45 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6524887 | 0.92 | NR4A2 (0.55) | NR4A2KCNH2CYP11B1CYP11B2TOP2A | |
| SCHEMBL6525040 | 0.92 | CYP11B1 (0.54) | NR4A2KCNH2CYP11B1CYP11B2TOP2A | |
| SCHEMBL6522276 | 0.90 | NR4A2 (0.64) | NR4A2KCNH2CYP11B1CYP11B2TOP2A | |
| SCHEMBL6518834 | 0.88 | NR4A2 (0.61) | NR4A2KCNH2CYP11B1CYP11B2TOP2A | |
| SCHEMBL3409155 | 0.87 | CYP11B1 (0.49) | NR4A2KCNH2CYP11B1CYP11B2SLC2A1 | |
| SCHEMBL3409535 | 0.81 | CYP11B1 (0.46) | NR4A2KCNH2CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL6525530 | 0.81 | CYP2C9 (0.60) | NR4A2KCNH2TOP2ASLC2A1SLC2A2 | |
| SCHEMBL6523043 | 0.80 | CYP11B2 (0.54) | NR4A2KCNH2CYP11B1CYP11B2SLC2A1 | |
| SCHEMBL16208210 | 0.78 | SLC2A2 (0.47) | TOP2ASLC2A1SLC2A2 | |
| SCHEMBL1472110 | 0.77 | NR4A2 (1.00) | NR4A2KCNH2CYP11B1CYP11B2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2262769-B1 | POLYSUBSTITUTED 2-ARYL-6-PHENYL-IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-11-05 | — | — | EP | claimed |
| US-8507520-B2 | Polysubstituted 2-aryl-6-phenylimidazo[1,2-A]pyridine derivatives, and preparation and therapeutic use thereof | SANOFI (FR) | 2013-08-13 | — | — | US | claimed |
| US-20110065745-A1 | POLYSUBSTITUTED 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-17 | — | — | US | claimed |
| EP-2262769-B1 | POLYSUBSTITUTED 2-ARYL-6-PHENYL-IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-11-05 | — | — | EP | disclosed |
| US-20110065745-A1 | POLYSUBSTITUTED 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065745-A1 | POLYSUBSTITUTED 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF | JAK2, ABL1, REN | NR4A2 1394/4885KCNH2 1641/4885CYP11B1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.